Cyclophosphamide and bortezomib with prednisone or dexamethasone for the treatment of relapsed and refractory multiple myeloma
Clinical trials of the combination of cyclophosphamide, bortezomib and steroids in relapsed/refractory myeloma have shown promising results, but there is little information about real-world outcomes. We retrospectively reviewed the results of weekly CyBorP(D) in 96 patients treated off study. The overall response rate was 69%; median PFS was 16.2 months. Toxicity was mild with low rates of myelosuppression and neuropathy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Donna E. Reece, Young Trieu, Esther Masih-Khan, Eshetu G. Atenafu, Christine Chen, Anca Prica, Rodger Tiedemann, Suzanne Trudel, Vishal Kukreti Tags: Original Study Source Type: research
More News: Clinical Trials | Dexamethasone | Hematology | Leukemia | Lymphoma | Myeloma | Neurology | Prednisone | Study | Toxicology | Velcade